Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.41 |
| ▸ | SMO | Q99835 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 4/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908087 | 1.00 | SYK (0.41) | SYKSMOS1PR1ACACBMAP3K12 | |
| SCHEMBL907876 | 0.92 | SMO (0.46) | SYKSMOS1PR1ACACBMAP3K12 | |
| SCHEMBL908599 | 0.92 | SMO (0.46) | SYKSMOS1PR1ACACBMAP3K12 | |
| SCHEMBL908278 | 0.92 | SMO (0.46) | SYKSMOS1PR1ACACBMAP3K12 | |
| SCHEMBL907875 | 0.92 | SMO (0.46) | SYKSMOS1PR1ACACBMAP3K12 | |
| SCHEMBL908261 | 0.92 | SMO (0.46) | SYKSMOS1PR1ACACBMAP3K12 | |
| SCHEMBL908311 | 0.91 | SMO (0.42) | SYKSMOS1PR1MAP3K12 | |
| SCHEMBL908312 | 0.91 | SMO (0.42) | SYKSMOS1PR1MAP3K12 | |
| SCHEMBL908078 | 0.86 | SMO (0.41) | SMO | |
| SCHEMBL908079 | 0.86 | SMO (0.41) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | GPR88, PIGO, PRLHR | SYK 2213/4885SMO 1520/4885S1PR1 513/4885 |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | GPR88, PRLHR, GPR68 | SYK 2295/4885SMO 1476/4885S1PR1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.